68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
As an emerging molecule targeting FAP, 68Ga-FAP-CHX is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAP-CHX in patients with various types of cancer and compared them with the results of 68Ga-FAPI-04 or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAP-CHX.
Epistemonikos ID: 2b3180b5f90f98063e6d1cd04c2020b2090e7ee8
First added on: May 13, 2024